$0.11
0.93% yesterday
Nasdaq, Dec 23, 10:00 pm CET
ISIN
US18978H1023
Symbol
CNSP
Sector
Industry

Cns Pharmaceuticals Inc Stock price

$0.11
-0.01 5.22% 1M
-2.12 95.11% 6M
-63.39 99.83% YTD
-60.39 99.82% 1Y
-1,300.84 99.99% 3Y
-5,789.89 100.00% 5Y
-6,854.89 100.00% 10Y
Nasdaq, Closing price Mon, Dec 23 2024
+0.00 0.93%
ISIN
US18978H1023
Symbol
CNSP
Sector
Industry

Key metrics

Market capitalization $6.27m
Enterprise Value $-670.00k
P/E (TTM) P/E ratio 0.00
EV/FCF (TTM) EV/FCF 0.05
P/B ratio (TTM) P/B ratio 1.09
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-17.08m
Free Cash Flow (TTM) Free Cash Flow $-14.18m
Cash position $6.97m
EPS (TTM) EPS $-75.02
P/E forward negative
Short interest 2.79%
Show more

Is Cns Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.

Cns Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Cns Pharmaceuticals Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Cns Pharmaceuticals Inc:

Buy
100%

Financial data from Cns Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.01 5.01
8% 8%
-
- Research and Development Expense 12 12
8% 8%
-
-17 -17
8% 8%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -17 -17
8% 8%
-
Net Profit -17 -17
10% 10%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cns Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cns Pharmaceuticals Inc Stock News

Neutral
Accesswire
19 days ago
Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure Register for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company")...
Neutral
Accesswire
29 days ago
Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 HOUSTON, TX / ACCESSWIRE / November 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treat...
Neutral
Accesswire
about one month ago
HOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract has been selected for poster presentation at the 29th Annual Meeting of the Society for Neuro-...
More Cns Pharmaceuticals Inc News

Company Profile

CNS Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, focuses on the development of anti-cancer drug candidates for the treatment of primary and metastatic brain, and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma. It has a development agreement with WPD Pharmaceuticals Inc. for the development of several preclinical drug candidates including WP1122, which will be tested on a range of viruses, including the coronavirus SARS-CoV-2. CNS Pharmaceuticals, Inc. was founded in 2017 and is based in Houston, Texas.

Head office United States
CEO John Climaco
Employees 5
Founded 2017
Website www.cnspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today